{
  "id": 10946871,
  "title": "Sagimet stock surges on positive acne trial data",
  "url": "https://urgent.news/2026/09/30/sagimet-stock-surges-on-positive-acne-trial-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T13:13:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/sagimet-stock-surges-on-positive-acne-trial-data-4925262"
  },
  "original_language": "en",
  "account": null,
  "summary": "Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares surged over 12% in premarket trading on Wednesday after receiving positive results from its license partner Ascletis' Phase 3 open-label extension trial of denifanstat for moderate to severe acne. The trial demonstrated that denifanstat achieved a 57% treatment success rate, with significant reductions in total lesions (72%) and inflammatory lesions (77%) after 52 weeks of treatment. The drug was also generally well-tolerated, with no adverse event-related permanent discontinuations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}